高密度脂蛋白与心血管疾病。
HDL and cardiovascular disease.
机构信息
South Australian Health and Medical Research Institute, Adelaide, SA, Australia; Monash University, Adelaide, SA, Australia.
South Australian Health and Medical Research Institute, Adelaide, SA, Australia.
出版信息
Pathology. 2019 Feb;51(2):142-147. doi: 10.1016/j.pathol.2018.10.017. Epub 2019 Jan 3.
High-density lipoprotein (HDL) has received increasing interest due to observations of an inverse relationship between its systemic levels and cardiovascular risk and targeted interventions in animal models that have had favourable effects on atherosclerotic plaque. In addition to its pivotal role in reverse cholesterol transport, HDL has been reported to possess a range of functional properties, which may exert a protective influence on inflammation, oxidation, angiogenesis and glucose homeostasis. This has led to the development of a range of HDL targeted therapeutics, which have undergone evaluation in clinical trials. The current state of HDL in cardiovascular prevention will be reviewed.
高密度脂蛋白（HDL）因其与心血管风险呈负相关的系统水平以及动物模型中靶向干预的观察结果而受到越来越多的关注，这些干预对动脉粥样硬化斑块产生了有利影响。除了在胆固醇逆转运中的关键作用外，HDL 还被报道具有一系列功能特性，这些特性可能对炎症、氧化、血管生成和葡萄糖稳态产生保护作用。这导致了一系列针对 HDL 的治疗药物的发展，并在临床试验中进行了评估。本文将对心血管预防中 HDL 的现状进行综述。
Zotero 插件